Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Single-Dose, 2 Period Crossover Pharmacokinetic and Bioequivalence Study, With a Lead-In Dose Period, Evaluating Oral Abacavir Acetate (Prurisol) and Oral Abacavir Sulfate (Ziagen) in Healthy Volunteers

Trial Profile

A Randomized, Open-Label, Single-Dose, 2 Period Crossover Pharmacokinetic and Bioequivalence Study, With a Lead-In Dose Period, Evaluating Oral Abacavir Acetate (Prurisol) and Oral Abacavir Sulfate (Ziagen) in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abacavir (Primary)
  • Indications Psoriasis
  • Focus First in man; Pharmacokinetics
  • Sponsors Cellceutix
  • Most Recent Events

    • 24 Sep 2014 Status changed from active, no longer recruiting to completed.
    • 07 Aug 2014 Results of primary endpoint published in Cellceutix media release.
    • 07 Aug 2014 Primary endpoint (bioequivalence of Prurisol and Ziagen, as determined by AUC) has been met, according to Cellceutix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top